Vanguard Group
CTSO icon

Vanguard Group’s Cytosorbents Corp CTSO Stock Holding History

Vanguard Group’s Portfolio CTSO Stock Details CTSO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$1.41M Hold
2,204,294
– – ﹤0.01% 3682
2025
Q3 		$2.06M Buy
2,204,294
+79,535
+4% +$78.3K ﹤0.01% 3573
2025
Q2 		$2.72M Buy
2,124,759
+175,208
+9% +$176K ﹤0.01% 3429
2025
Q1 		$1.95M Hold
1,949,551
– – ﹤0.01% 3498
2024
Q4 		$1.77M Hold
1,949,551
– – ﹤0.01% 3601
2024
Q3 		$2.92M Hold
1,949,551
– – ﹤0.01% 3444
2024
Q2 		$1.37M Hold
1,949,551
– – ﹤0.01% 3690
2024
Q1 		$1.85M Hold
1,949,551
– – ﹤0.01% 3618
2023
Q4 		$2.16M Hold
1,949,551
– – ﹤0.01% 3578
2023
Q3 		$3.67M Hold
1,949,551
– – ﹤0.01% 3376
2023
Q2 		$7M Sell
1,949,551
-7,277
-0.4% -$23K ﹤0.01% 3141
2023
Q1 		$6.59M Hold
1,956,828
– – ﹤0.01% 3174
2022
Q4 		$3.03M Buy
1,956,828
+885
+0% +$1.31K ﹤0.01% 3514
2022
Q3 		$2.66M Hold
1,955,943
– – ﹤0.01% 3626
2022
Q2 		$4.28M Sell
1,955,943
-237,979
-11% -$546K ﹤0.01% 3458
2022
Q1 		$7M Sell
2,193,922
-15,243
-0.7% -$54.6K ﹤0.01% 3346
2021
Q4 		$9.26M Buy
2,209,165
+336,549
+18% +$1.89M ﹤0.01% 3258
2021
Q3 		$15.2M Sell
1,872,616
-239,951
-11% -$1.95M ﹤0.01% 3008
2021
Q2 		$15.9M Buy
2,112,567
+10,629
+0.5% +$89.6K ﹤0.01% 2952
2021
Q1 		$18.2M Sell
2,101,938
-119,668
-5% -$1.14M ﹤0.01% 2834
2020
Q4 		$17.7M Buy
2,221,606
+325,355
+17% +$2.72M ﹤0.01% 2699
2020
Q3 		$15.1M Buy
1,896,251
+303,437
+19% +$2.74M ﹤0.01% 2585
2020
Q2 		$15.8M Buy
1,592,814
+182,580
+13% +$1.68M ﹤0.01% 2540
2020
Q1 		$10.9M Buy
1,410,234
+5,768
+0.4% +$29.1K ﹤0.01% 2578
2019
Q4 		$5.41M Sell
1,404,466
-4,430
-0.3% -$19.3K ﹤0.01% 3144
2019
Q3 		$7.09M Buy
1,408,896
+33,189
+2% +$193K ﹤0.01% 3001
2019
Q2 		$9.09M Buy
1,375,707
+6,698
+0.5% +$46K ﹤0.01% 2913
2019
Q1 		$10.4M Buy
1,369,009
+66,283
+5% +$516K ﹤0.01% 2803
2018
Q4 		$10.5M Buy
1,302,726
+74,610
+6% +$741K ﹤0.01% 2752
2018
Q3 		$15.8M Sell
1,228,116
-27,645
-2% -$347K ﹤0.01% 2696
2018
Q2 		$14.3M Buy
1,255,761
+257,035
+26% +$2.43M ﹤0.01% 2723
2018
Q1 		$7.04M Buy
998,726
+147,150
+17% +$1.11M ﹤0.01% 2994
2017
Q4 		$5.54M Buy
851,576
+51,644
+6% +$329K ﹤0.01% 3095
2017
Q3 		$4.96M Buy
799,932
+347,876
+77% +$1.77M ﹤0.01% 3122
2017
Q2 		$1.94M Sell
452,056
-115,060
-20% -$504K ﹤0.01% 3388
2017
Q1 		$2.55M Buy
567,116
+21,312
+4% +$119K ﹤0.01% 3301
2016
Q4 		$2.98M Sell
545,804
-12,539
-2% -$68.6K ﹤0.01% 3231
2016
Q3 		$3.57M Buy
558,343
+20,636
+4% +$107K ﹤0.01% 3157
2016
Q2 		$2.45M Buy
537,707
+5,446
+1% +$23.7K ﹤0.01% 3302
2016
Q1 		$2.09M Buy
532,261
+24,198
+5% +$105K ﹤0.01% 3363
2015
Q4 		$2.83M Buy
508,063
+16,435
+3% +$112K ﹤0.01% 3255
2015
Q3 		$3.1M Buy
491,628
+14,191
+3% +$94.7K ﹤0.01% 3180
2015
Q2 		$2.93M Buy
477,437
+229,160
+92% +$1.56M ﹤0.01% 3250
2015
Q1 		$3.27M Buy
+248,277
New +$2.55M ﹤0.01% 3199

Other funds holding CTSO

AC
Avenir Corporation Alexandria, Virginia $820M AUM 2.4% 1-Year Est. Return
SC
Skylands Capital Milwaukee, Wisconsin $763M AUM 26.49% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
CIBC Private Wealth Group
CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group's CTSO Position: Q4 2025 in Review

Vanguard Group held its Cytosorbents Corp (CTSO) position steady in Q4 2025 at 2,204,294 shares worth $1.41M. The position accounts for ﹤0.01% of the portfolio, ranked #3682.

Vanguard Group first reported a position in CTSO in Q1 2015 and has held it in 44 quarters since. The position peaked at $18.2M in Q1 2021. 51 funds tracked by Wall St. Rank hold CTSO as of Q4 2025.

  • Vanguard Group held 2,204,294 shares of Cytosorbents Corp worth $1.41M as of Q4 2025.
  • Vanguard Group left its Cytosorbents Corp share count unchanged in Q4 2025.
  • Cytosorbents Corp made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3682 holding.
  • Vanguard Group first reported a position in Cytosorbents Corp in Q1 2015 and has held it in 44 quarters since.
  • Vanguard Group's Cytosorbents Corp position peaked at $18.2M in Q1 2021.
  • 51 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.